Junji Uchino

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 101 publications

Estimation of Excess Extracellular Fluid Volume Using Blood Volume Monitoring: A Comparison With Bioimpedance Spectroscopy. A Pilot Study.

Estimation of Excess Extracellular Fluid Volume Using Blood Volume Monitoring: A Comparison With Bioimpedance Spectroscopy. A Pilot Study.

Journal: Hemodialysis international. International Symposium on Home Hemodialysis

Published: January 07, 2026

A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).

A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).

Journal: Journal of cachexia, sarcopenia and muscle

Published: November 20, 2025

Pressor Response Index During Blood Return as a Marker for Identifying Intradialytic Hypotension.

Pressor Response Index During Blood Return as a Marker for Identifying Intradialytic Hypotension.

Journal: Hemodialysis international. International Symposium on Home Hemodialysis

Published: November 13, 2025

A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.

A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 08, 2023

Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.

Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.

Journal: Cancer medicine

Published: March 07, 2023

A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study).

A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study).

Journal: Translational lung cancer research

Published: February 23, 2023

Changes in blood pressure and arterial stiffness monitored using the cardio-ankle vascular index during hemodialysis.

Changes in blood pressure and arterial stiffness monitored using the cardio-ankle vascular index during hemodialysis.

Journal: Frontiers in physiology

Published: December 28, 2022

Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations.

Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations.

Journal: Proteomes

Published: November 08, 2022

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.

Journal: The oncologist

Published: October 12, 2022

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial.

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial.

Journal: JTO clinical and research reports

Published: August 15, 2022

Expert consensus on perioperative treatment for non-small cell lung cancer.

Expert consensus on perioperative treatment for non-small cell lung cancer.

Journal: Translational lung cancer research

Published: April 18, 2022

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.

Journal: The oncologist

Published: April 08, 2022

Showing 1-12 of 101

Last Updated: 09/26/2026